BCL2 and plasma cell myeloma: For the mitochondria-targeted BCL-2 inhibitor venetoclax, clinical trials have revealed that secondary resistance can arise in multiple myeloma patients who have undergone long-term venetoclax therapy or possess missense mutations in BCL-2 and BAX.